Status:
UNKNOWN
Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)
Lead Sponsor:
OBS Pakistan
Conditions:
Chronic Stable Angina
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
The rationale of MIDA trial is to determine efficacy and tolerability of ranolazine molecule among Pakistan population and obtain firsthand knowledge about the molecule ranolazine.
Eligibility Criteria
Inclusion
- Patients with diagnosis of coronary artery disease (CAD)
- Patients present with the symptoms of stable angina after withdrawn from other antianginal drugs and given the required background therapy for at least 7 days will be qualified for entering this study and performing 1st ETT qualifying test
- Patients developed exercise-induced ECG ischemiai during two qualifying exercise treadmill testsii.
- Willing and able to provide a written informed consent
Exclusion
- • Factors that might compromise ECG or ETT interpretation
- Patients with resting ST-segment depression ≥ 1mm in any lead
- Left bundle-branch block
- Patients implanted with pacemaker
- Patients under Digitalis therapy
- Patients with family history of (or congenital) long QT syndrome
- Patients with congenital heart disease
- Patients with uncorrected valvular heart disease
- Patients with unstable angina, or MI, or coronary revascularization procedure ≤ 2 months prior enter this study
- Female who is pregnant/lactating or planning to be pregnant, or female of childbearing potential\* who is not using medically recognized method of contraception
- \*Other than those who have been surgically sterilized (defined as having undergone hysterectomy or bilateral oophorectomy or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal.
- • Patients are under any one of the following conditions:
- New York Heart Association (NYHA) Class III or Class IV congestive heart failure (CHF)
- QTc \> 450 msec at screening
- Active myocarditis, pericarditis, hypertrophic cardiomyopathy
- Uncontrolled hypertension (defined as SBP \> 180 mmHg) Voltage criteria for left ventricular hypertrophy in the absence of repolarization abnormalities will not be exclusion criteria
- Use of any investigational product ≤ 4 weeks prior to screening
- Patients with severe hepatic disease (e.g., liver cirrhosis)
- Patients with impaired renal function (defined as serum Cr \>1.5 mg/dl)
- Patients with any condition or disease which is considered not suitable for this study by investigator
Key Trial Info
Start Date :
April 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2018
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT03486561
Start Date
April 1 2018
End Date
October 31 2018
Last Update
April 3 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.